The stocks in this article have caught Wall Street’s attention in a big way, with price targets implying returns above 20%. But investors should take these forecasts with a grain of salt because analysts typically say nice things about companies so their firms can win business in other product lines like M&A advisory.
At StockStory, we look beyond the headlines with our independent analysis to determine whether these bullish calls are justified. Keeping that in mind, here are three stocks where Wall Street’s enthusiasm may be misplaced and some other investments worth exploring instead.
Gibraltar (ROCK)
Consensus Price Target: $85 (39% implied return)
Gibraltar (NASDAQ: ROCK) makes renewable energy, agriculture technology and infrastructure products. Its mission statement is to make everyday living more sustainable.
Why Are We Wary of ROCK?
- Annual sales declines of 5.4% for the past two years show its products and services struggled to connect with the market during this cycle
- Gross margin of 25.4% is below its competitors, leaving less money to invest in areas like marketing and R&D
Gibraltar’s stock price of $61.16 implies a valuation ratio of 12.2x forward P/E. To fully understand why you should be careful with ROCK, check out our full research report (it’s free).
Repligen (RGEN)
Consensus Price Target: $179.72 (50.2% implied return)
With over 13 strategic acquisitions since 2012 to build its comprehensive bioprocessing portfolio, Repligen (NASDAQ: RGEN) develops and manufactures specialized technologies that improve the efficiency and flexibility of biological drug manufacturing processes.
Why Is RGEN Risky?
- Core business is underperforming as its organic revenue has disappointed over the past two years, suggesting it might need acquisitions to stimulate growth
- Efficiency has decreased over the last five years as its adjusted operating margin fell by 16.9 percentage points
- Shrinking returns on capital from an already weak position reveal that neither previous nor ongoing investments are yielding the desired results
At $119.65 per share, Repligen trades at 63.1x forward P/E. Check out our free in-depth research report to learn more about why RGEN doesn’t pass our bar.
Sallie Mae (SLM)
Consensus Price Target: $39 (26.5% implied return)
Originally created as a government-sponsored enterprise before privatizing in 2004, Sallie Mae (NASDAQ: SLM) is a financial services company that provides private education loans, savings products, and educational resources to help students and families pay for college.
Why Is SLM Not Exciting?
- Sales tumbled by 1.6% annually over the last five years, showing market trends are working against its favor during this cycle
Sallie Mae is trading at $30.84 per share, or 10.1x forward P/E. If you’re considering SLM for your portfolio, see our FREE research report to learn more.
Stocks We Like More
When Trump unveiled his aggressive tariff plan in April 2025, markets tanked as investors feared a full-blown trade war. But those who panicked and sold missed the subsequent rebound that’s already erased most losses.
Don’t let fear keep you from great opportunities and take a look at Top 5 Strong Momentum Stocks for this week. This is a curated list of our High Quality stocks that have generated a market-beating return of 183% over the last five years (as of March 31st 2025).
Stocks that made our list in 2020 include now familiar names such as Nvidia (+1,545% between March 2020 and March 2025) as well as under-the-radar businesses like the once-small-cap company Exlservice (+354% five-year return). Find your next big winner with StockStory today for free. Find your next big winner with StockStory today. Find your next big winner with StockStory today
StockStory is growing and hiring equity analyst and marketing roles. Are you a 0 to 1 builder passionate about the markets and AI? See the open roles here.
